Rob van Wijk

Publications

• Systems pharmacology of hepatic metabolism in zebrafish larvae
• Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat
• Pharmacokinetic Modeling of Paracetamol Uptake and Clearance in Zebrafish Larvae: Expanding the Allometric Scale in Vertebrates with Five Orders of Magnitude.
• Integration of PKPD relationships into benefit-risk analysis.
• Multi-modal 3D reconstruction and measurements of zebrafish larvae and its organs using axial-view microscopy
• Outside‐In Systems Pharmacology Combines Innovative Computational Methods With High‐Throughput Whole Vertebrate Studies
• Impact of post-hatching maturation on the pharmacokinetics of paracetamol in zebrafish larvae.
• Mechanistic and quantitative understanding of pharmacokinetics in zebrafish larvae through nanoscale blood sampling and metabolite modelling of paracetamol
• Translational pharmacokinetics-pharmacodynamics in zebrafish: integration of experimental and computational methods
• Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations
• Quantification of natural growth of two strains of Mycobacterium marinum for translational anti‐tuberculosis drug development
• Anti‐tuberculosis effect of isoniazid scales accurately from zebrafish to humans
• Segmentation-driven Optimization for Iterative Reconstruction in Optical Projection Tomography: An Exploration
• Pharmacokinetic Modeling of Paracetamol Uptake and Clearance in Zebrafish Larvae: Expanding the Allometric Scale in Vertebrates with Five Orders of Magnitude
• Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in nonanesthetized rat
• Outside-in systems pharmacology combines innovative computational methods with high-throughput whole vertebrate studies
• Impact of post-hatching maturation on the pharmacokinetics of paracetamol in zebrafish larvae
• Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans
• Integration of PKPD relationships into benefit-risk analysis
• Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial
• Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
• Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application
• Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs
• Implementing best practices on data generation and reporting of mycobacterium tuberculosis in vitro assays within the ERA4TB consortium
• Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
• Pharmacokinetic analysis across studies to drive knowledge‐integration
• Seasonal influence on respiratory tract infection severity including COVID‐19 quantified through Markov Chain modeling
• Model‐informed pediatric dose selection of marzeptacog alfa (activated): an exposure matching strategy
• Pharmacokinetic modeling of paracetamol uptake and clearance in zebrafish larvae
• Immunobiology and pharmacology of neuropeptide substance P
• Risk factors for COVID-19 and respiratory tract infections during the Coronavirus pandemic
• Selection and prioritization of candidate combination regimens for the treatment of tuberculosis.
• Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19.
• Predicting tuberculosis drug efficacy in preclinical and clinical models from in vitro data